1. Impactful Data in TD That Can Guide Treatment Decisions

2. Program Introduction

3. This program will include a discussion of investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. TD Epidemiology, Healthcare Use, and the Educational Needs of TD Healthcare Providers

5. Incidence and Prevalence of TD: US Data

6. TD Global Prevalence With SGAs

7. TD Global Prevalence With SGAs (cont)

8. Healthcare Use and Costs for Patients With TD

9. Educational Needs of Physicians Treating TD

10. Summary

11. How TD Affects Quality of Life and Function

12. Study on How TD Affects QoL: Design

13. Study on How TD Affects QoL: Interim Results

14. Brief History of TD

15. Effects of TD on Daily Life

16. Treating TD Symptoms

17. Managing TD From a Nursing Perspective

18. TD From an Historical Perspective and Strategies for Improved Management With Currently Approved VMAT2 Inhibitors

19. Where Does TD Fit In?

20. 5 Steps to Improving TD Management

21. Deutetrabenazine in AIM-TD: NNT and NNH

22. Deutetrabenazine AEs

23. Valbenazine in KINECT3: NNT

24. Valbenazine in KINECT3: NNH and AEs

25. Conclusions

26. VMAT2 Inhibitors

27. Open-Label Extension Study on Long-Term Safety of Deutetrabenazine

28. Pooled Analysis on Long-Term Safety of Valbenazine

29. Pooled Analysis on Cardiovascular Safety of Valbenazine

30. Establishing an MCID for AIMS Score Change

31. Risk Factors for TD and Efficacy of VMAT2 Inhibitors

32. Risk Factors for TD

33. Valbenazine for TD in Schizophrenia and Schizoaffective Disorders: KINECT3 Findings

34. Valbenazine for TD in Mood Disorders: KINECT3 Findings

35. Systematic Review of VMAT2 Inhibitors in TD

36. Abbreviations

37. Abbreviations (cont)